T1	Participants 97 123	group III rhabdomyosarcoma
T2	Participants 352 384	osteosarcoma and Ewing's sarcoma
T3	Participants 433 473	patients with group III rhabdomyosarcoma
T4	Participants 599 743	444 group III patients who received induction therapy, had response assessed at week 8 by anatomic imaging, and continued with protocol therapy.
